Table 1 Summary of demographic and baseline characteristics of randomized patients
Total No. of randomized patients, no (%) | 226 (100) | |
Female, no. (%) | 130 (57.5) | |
Race, no. (%) | White | 174 (77) |
Black African/Asian | 44 (19.5) | |
Other | 8 (3.5) | |
Age, mean (SD) | 47.1 (13.7) | |
Body mass index (kg/m2), mean (SD) | 31.1 (6.7) | |
Smoking history, no. (%) | Never smoked | 163 (72.1) |
Ex-smoker | 63 (27.9) | |
Characteristics | ||
FEV1 (L), mean (SD) | 2.075 (0.630) | |
% predicted FEV1, mean (SD) | 63.4 (11.3) | |
FEV1/FVC (%), mean (SD) | 64.4 (10.3) | |
FEV1 reversibility (%), mean (SD) | 25.7 (15.6) | |
ACQ score, mean (SD) | 2.46 (0.57) | |
Mini-AQLQ score, mean (SD) | 4.52 (1.04) | |
Open-label albuterol usea, mean (SD) | 3.63 (1.62) | |
Controller: ICS + LABA during the cross-over phase (%) | 160 (70.8) | |
Controller: ICS (low doseb) (%) | 52 (23.0) | |
Controller: ICS (medium doseb) (%) | 157 (69.5) | |
Controller: ICS (high doseb) (%) | 17 (7.5) | |